West 4Q Revenues: $415.6 million (+9%) 4Q Earnings: n/a (earnings were $39.1 million 4Q16) FY Revenues: $1.6 billion(+6%) FY Earnings: $150.7 million (+9%) Comments: Proprietary Products segment sales were up 6% to $306.4 million in the quarter led by double-digit growth in Biologics and high-single digit growth in Generics, offset by a low-single digit decline in Pharma. Contract-Manufactured Products segment sales were up 18% to $109.2 million. During the three and twelve months ended Dec...